Thermal ablation techniques for tumor treatment: open measurement issues from research to industry

Author(s):  
G. Cerro ◽  
L. Ferrigno ◽  
G. Miele
2020 ◽  
Vol 21 (12) ◽  
pp. 4398 ◽  
Author(s):  
Lucile Dumolard ◽  
Julien Ghelfi ◽  
Gael Roth ◽  
Thomas Decaens ◽  
Zuzana Macek Jilkova

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related deaths worldwide and its incidence is rising. Percutaneous locoregional therapies, such as radiofrequency ablation and microwave ablation, are widely used as curative treatment options for patients with small HCC, but their effectiveness remains restricted because of the associated high rate of recurrence, occurring in about 70% of patients at five years. These thermal ablation techniques have the particularity to induce immunomodulation by destroying tumours, although this is not sufficient to raise an effective antitumour immune response. Ablative therapies combined with immunotherapies could act synergistically to enhance antitumour immunity. This review aims to understand the different immune changes triggered by radiofrequency ablation and microwave ablation as well as the interest in using immunotherapies in combination with thermal ablation techniques as a tool for complementary immunomodulation.


2014 ◽  
Vol 24 (8) ◽  
pp. 1971-1980 ◽  
Author(s):  
F. Deschamps ◽  
G. Farouil ◽  
N. Ternes ◽  
A. Gaudin ◽  
A. Hakime ◽  
...  

HPB ◽  
2020 ◽  
Vol 22 ◽  
pp. S268
Author(s):  
M. Di Martino ◽  
G. Rompianesi ◽  
I. Mora-Guzmán ◽  
E Martín Pérez ◽  
R. Montalti ◽  
...  

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 437-437
Author(s):  
Margarida Matias ◽  
Frederic Deschamps ◽  
Laurence Albiges ◽  
Yohann Loriot ◽  
Christophe Massard ◽  
...  

437 Background: Local treatment of BM in mRCC pts comprises different approaches including thermal ablation techniques as well as radiofrequency ablation (RFA) and cryotherapy. We report our experience for the treatment of BM of mRCC pts using thermal ablation. Methods: The medical records of all pts with mRCC submitted to thermal ablation of BM from Feb 2008 to Oct 2013 were retrospectively analyzed. Intention of treatment was recorded in 3 categories: complete treatment of all BM in pts with oligometastatic disease or prevention of skeletal related events (SRE) risk and/or pain relief in pts with multimetastatic disease. The local control rate and prognostic factors for local failure (LF) were analyzed including patient characteristics, extension of disease, BM characteristics and type of treatment. Results: 22 pts with BM of mRCC were treated by thermal ablation techniques, with 32 procedures (3 pts had >=3 BM treated). Histology of primary tumor was clear cell in 20 and chromophobe carcinoma in 2 pts. At time of BM treatment, Heng prognostic score was good, intermediate and poor in 36, 59 and 5% of pts. Median age was 67 yrs (48-85). A majority of men were treated (16/22=73%). In 34%, pts had BM synchronous with the primary. BM presented cortical bone erosion in 69% and neurological structures in the vicinity in 50%. Intention of treatment was complete control of BM in 43% and prevention of risk of SRE and/or pain relief in 57% of pts. Cryotherapy was performed in 72% and RF in 28% of cases. Concomitant cimentoplasty and arterial embolization was performed in 70% and 30% respectively. Pain relief was achieved in 81% of pts. LF occurred in 19% of pts (n=6) (95% CI: 4-33%). The median follow-up was 13.4 months (95% CI: 11-21). Median OS was not reached. 86% of pts are still alive at 12 months. The unfavorable prognostic factors for LF were BM size >50 mm (p=0.035) and neurological structures in the vicinity (p=0.0083). Conclusions: Thermal ablation techniques are treatment options that should be considered in the curative and palliative treatment of BM in pts with mRCC. When indications are carefully discussed, these techniques have the potential to achieve good local control and acceptable survival.


2017 ◽  
Vol 34 (03) ◽  
pp. 280-287 ◽  
Author(s):  
Raja Shaikh

AbstractUnderstanding and management of vascular anomalies has always been intriguing. These disorders exhibit an expected pattern of clinical presentation and progression, and characteristic imaging findings. Significant progress in understanding and treating patients with vascular anomalies has been made in the past quarter century. Newer multidisciplinary domains for treating these disorders with medical drugs and less invasive image-guided or surgical procedures are constantly evolving. Vascular anomalies can exhibit aggressive tumor-like behavior resulting in recurrence or persistent symptoms after treatment. Thermal ablation has been widely used in tumor treatment. This has generated interest on using thermal ablation for treating vascular anomalies. Percutaneous image-guided cryoablation is increasingly used for this purpose as compared with other ablation technologies. Availability of small caliber cryoprobes and the ability to monitor the freeze zone in real time have made this an attractive option to interventional radiologists. These experiences are relatively new and limited. It is helpful to understand the emerging role of this technology in the treatment of vascular anomalies.


2013 ◽  
Vol 29 (2) ◽  
pp. 493-499 ◽  
Author(s):  
Damian Kelleher ◽  
Tristan R. A. Lane ◽  
Ian J Franklin ◽  
Alun H Davies

Sign in / Sign up

Export Citation Format

Share Document